| Dr Michael J Weiss, MD | |
|
63 Barkley Cir, Ste. 100 & 101, Fort Myers, FL 33907-4514 | |
| (239) 938-3500 | |
| (239) 278-0588 |
| Full Name | Dr Michael J Weiss |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 36 Years |
| Location | 63 Barkley Cir, Fort Myers, Florida |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043258890 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | ME0066135 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lee Memorial Hospital | Fort myers, FL | Hospital |
| Gulf Coast Medical Center Lee Health | Fort myers, FL | Hospital |
| Cape Coral Hospital | Cape coral, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Radiology Leasing Llc | 1759327356 | 26 |
| Florida Radiology Consultants P A | 3678471943 | 45 |
News Archive
A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.
Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.
A new study has shown that effective opioid-sparing anaesthesia with dexmedetomidine can be guided with NOL pain monitoring technology (Medasense, Israel). The study showed that the NOL monitor is able to detect the effect of dexmedetomidine on the patient's pain response and enable administration of less intraoperative opioids.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
› Verified 6 days ago
| Entity Name | Florida Radiology Consultants P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518911668 PECOS PAC ID: 3678471943 Enrollment ID: O20031223000475 |
News Archive
A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.
Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.
A new study has shown that effective opioid-sparing anaesthesia with dexmedetomidine can be guided with NOL pain monitoring technology (Medasense, Israel). The study showed that the NOL monitor is able to detect the effect of dexmedetomidine on the patient's pain response and enable administration of less intraoperative opioids.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
› Verified 6 days ago
| Entity Name | Florida Radiology Leasing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518907823 PECOS PAC ID: 1759327356 Enrollment ID: O20050706000059 |
News Archive
A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.
Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.
A new study has shown that effective opioid-sparing anaesthesia with dexmedetomidine can be guided with NOL pain monitoring technology (Medasense, Israel). The study showed that the NOL monitor is able to detect the effect of dexmedetomidine on the patient's pain response and enable administration of less intraoperative opioids.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Weiss, MD 8601 Belle Meade Dr, Fort Myers, FL 33908-6015 Ph: (239) 454-2666 | Dr Michael J Weiss, MD 63 Barkley Cir, Ste. 100 & 101, Fort Myers, FL 33907-4514 Ph: (239) 938-3500 |
News Archive
A research breakthrough has proven that it is possible to reprogram mature cells from human skin directly into brain cells, without passing through the stem cell stage. The unexpectedly simple technique involves activating three genes in the skin cells; genes which are already known to be active in the formation of brain cells at the foetal stage.
Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.
A new study has shown that effective opioid-sparing anaesthesia with dexmedetomidine can be guided with NOL pain monitoring technology (Medasense, Israel). The study showed that the NOL monitor is able to detect the effect of dexmedetomidine on the patient's pain response and enable administration of less intraoperative opioids.
ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
› Verified 6 days ago
Stuart A Bobman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-2316 | |
Victor H Gregory, DO Radiology Medicare: Not Enrolled in Medicare Practice Location: 3680 Broadway, Fort Myers, FL 33901 Phone: 239-936-2316 | |
Dr. Mai F Saif, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 63 Barkley Cir, Ste. 100 & 101, Fort Myers, FL 33907 Phone: 239-938-3500 Fax: 239-278-0588 | |
Dr. Thomas Anderson Elkins, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-4068 Fax: 239-936-6989 | |
Peter H. Blitzer, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 7341 Gladiolus Dr, Fort Myers, FL 33908 Phone: 239-489-3420 Fax: 239-489-3219 | |
William B Hearn, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 14551 Hope Center Loop Ste 100, Fort Myers, FL 33912 Phone: 239-936-2316 Fax: 239-936-3009 |